MVLA yields 666666.67% · ABBV yields 3.06%● Live data
📍 MVLA pulled ahead of the other in Year 1
Combined, MVLA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MVLA + ABBV for your $10,000?
Movella Holdings Inc. operates as a full-stack provider of integrated sensors, software, and analytics that enable the digitization of movement worldwide. The company offers Xsens motion capture hardware products, such as MVN Link, MVN Awinda, and MVN Awinda Starter; Xsens motion capture software products, including MVN Animate for entertainment applications and MVN Analyze for health and sports, and research, as well as cloud-based solutions to process and store data, and generate reports; MVN Processing to create motion capture media from a secure cloud-based platform; MVN Reports that presents kinematic data in a readable format; and Xsens Metaglove by Manus that uses high-fidelity finger tracking using sub-millimetre accurate fingertip tracking sensors. It also provides Xsens sensor modules for navigating, controlling, and detecting movement in industrial settings; and wearables comprising Movella DOT and MTw Awinda to track motion in various conditions with its body-worn sensors. In addition, the company offers Kinduct human performance platform, which includes tools to optimize athletic health and performance. It serves the entertainment, health and sports, and automation and mobility markets. The company is based in Henderson, Nevada.
Full MVLA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.